Neratinib in Combination With Ruxolitinib in Patients With mTNBC

This trial is studying a combination of two drugs — neratinib and ruxolitinib — for women with metastatic triple-negative breast cancer (TNBC), a type of breast cancer that is harder to treat because it doesn't respond to hormone therapies. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with metastatic TNBC - You have previously received standard chemotherapy (anthracycline and taxane-based), unless there was a medical reason not to - You have received no more than 4 prior chemotherapy regimens for metastatic disease (or more if your doctor approves and you are in good health) - You have a tumor site that is accessible for a biopsy (breast, chest wall, lung, liver, or skin) - You are in generally good health (ECOG 0–1) **You may NOT be eligible if...** - You have more than 4 prior chemotherapy regimens and are not in good health - You are unable to safely undergo a tumor biopsy - Your blood counts or organ function are too low to safely participate - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.